Published in:
01-10-2013 | Original Article
Predictors of long-term remission in patients with Graves’ disease: a single center experience
Authors:
Panagiotis Anagnostis, Fotini Adamidou, Stergios A. Polyzos, Simoni Katergari, Eleni Karathanasi, Chrisanthi Zouli, Athanasios Panagiotou, Marina Kita
Published in:
Endocrine
|
Issue 2/2013
Login to get access
Abstract
Antithyroid drugs (ATDs) remain the first-line therapy in patients with Graves’ disease (GD), despite a high relapse rate. The purpose of this study was to identify the predictors of remission in patients with GD treated with ATDs—retrospective study at an endocrine referral service in Northern Greece. Two-hundred and eleven patients met the study’s criteria. Females (p = 0.049), non-smokers (p = 0.017), patients without ophthalmopathy (p = 0.033), and those developing pharmaceutical hypothyroidism (p = 0.018) experienced longer duration of remission. Duration of remission was positively associated with therapy duration (r
s = 0.151, p = 0.030), maximum TSH levels during (r
s = 0.241, p = 0.001), at the end (r
s = 0.280, p < 0.001) and 3 months after therapy (r
s = 0.341, p = 0.003). There was a negative association with free T4 (FT4) (r
s = −0.426, p < 0.001) and free triiodothyronine (FT3) (r
s = −0.467, p = 0.038) levels at 6 months after ATDs discontinuation. In multiple-regression analysis, only duration of the first ATDs course for more than 24 months independently predicted duration of remission. Female gender, non-smoking, the absence of orbitopathy, treatment duration, pharmaceutical hypothyroidism, higher TSH levels during, at the end and 3 months after ATDs discontinuation, and lower FT4 and FT3 levels 6 months after therapy were associated with longer duration of remission. However, only duration of ATDs therapy for more than 24 months independently predicted predict long-term remission in GD.